Table 3.

Adjusted odds of poor pain control or other adverse reaction following the prescription of an opioid medication among poor/ultrarapid CYP2D6 metabolizers compared to intermediate to extensive metabolizers

CYP2D6 metabolizer status	Poor pain controla			Adverse reactiona			Any problema
	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
All patients	2.63	1.19, 5.83	0.02	1.77	0.87, 3.57	0.11	2.40	1.35, 4.28	0.003
Excluded patients prescribed a CYP2D6 inhibitor	2.15	0.87, 5.32	0.10	2.53	1.12, 5.70	0.03	2.68	1.39, 5.17	0.003
Excluded patients prescribed a CYP2D6 inhibitor and a *2A/*2A genotype	1.74	0.65, 4.66	0.27	2.51	1.07, 5.90	0.03	2.49	1.25, 4.95	0.01
Patients prescribed only oxycodone or hydrocodone, excluding patients prescribed a CYP2D6 inhibitor and a *2A/*2A genotype	1.71	0.55, 5.30	0.35	2.08	0.67, 6.49	0.21	2.23	0.94, 5.25	0.07

Notes:

^aResults are compared to intermediate to extensive CYP2D6 metabolizers and are adjusted for age and sex.